Profile
Harry Sacks worked as a Principal at Forest Laboratories, Inc. and as a Vice President-Clinical Development at Edge Therapeutics, Inc. He also worked as a VP-Medical Affairs & Medical Officer at OptiNose, Inc. from 2017 to 2022 and as a VP, Head-Respiratory & US Clinical Development at Novartis AG.
Dr. Sacks holds a doctorate degree from Albert Einstein College of Medicine, Inc.
Former positions of Harry Sacks
Companies | Position | End |
---|---|---|
OPTINOSE, INC. | Chief Tech/Sci/R&D Officer | 01/10/2022 |
NOVARTIS AG | Chief Tech/Sci/R&D Officer | - |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Corporate Officer/Principal | - |
FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Training of Harry Sacks
Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
OPTINOSE, INC. | Health Technology |
NOVARTIS AG | Health Technology |
Private companies | 2 |
---|---|
Forest Laboratories, Inc.
Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | Health Technology |
- Stock Market
- Insiders
- Harry Sacks